Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 1/20 | 0.53 |
| ▸ | BTK | Q06187 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 9/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1082504 | 0.88 | JAK3 (0.48) | BTKEGFRJAK3 | |
| SCHEMBL1025373 | 0.86 | STK17B (0.52) | CTSCBTKEGFRJAK3MET | |
| SCHEMBL1027584 | 0.86 | MAPT (0.51) | BTKEGFRJAK3ALDH1A1HTT | |
| SCHEMBL1072715 | 0.86 | CTSC (0.56) | CTSCKDR | |
| SCHEMBL4334439 | 0.84 | KMT2A (0.46) | BTKEGFRJAK3MEN1ALDH1A1 | |
| SCHEMBL4333056 | 0.83 | EGFR (0.41) | CTSCBTKEGFRJAK3MET | |
| SCHEMBL1025084 | 0.83 | JAK3 (0.42) | CTSCBTKEGFRJAK3LMNA | |
| SCHEMBL1024973 | 0.83 | CTSC (0.40) | CTSCBTKEGFRJAK3 | |
| SCHEMBL4364555 | 0.83 | JAK3 (0.43) | CTSCBTKEGFRJAK3KMT2A | |
| SCHEMBL4335022 | 0.83 | BTK (0.42) | CTSCBTKEGFRJAK3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | CTSC 1827/4885BTK 20/4885EGFR 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.